biotech · Systemic Lupus Erythematosus · Primary Progressive Multiple Sclerosis (PPMS) · ZBIO
Zenas BioPharma
Zenas BioPharma is a biotech organization headquartered in Waltham, USA. It trades on NYSE under ticker ZBIO. Primary therapeutic focus areas include Systemic Lupus Erythematosus, Primary Progressive Multiple Sclerosis (
1000 Winter St, Suite 1200, Waltham, MA 02451, US HQ
176 Employees
Public company Type
ZBIO · NYSE Ticker
Company details
- Status
- Public
- HQ
- 1000 Winter St, Suite 1200, Waltham, MA 02451, US
- Employees
- 176
- Programs
- 13
- Drugs
- 10
- Patents
- 0
Orelabrutinib
Phase 3 · small molecule · Multiple Sclerosis (MS) Primary Progressive
Orelabrutinib for Multiple Sclerosis (MS) Primary Progressive is a Phase 3 program (small_molecule) at Zenas BioPharma with 1 ClinicalTrials.gov record(s).
Internal code ZB020-03-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Zenas BioPharma
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Multiple Sclerosis (MS) Primary Progressive
- Status
- active
- Trials
- 1